Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial

dc.contributor.author	Ishola, David
dc.date.accessioned	2026-10-26T17:54:48Z
dc.date.issued	2021-09-13
dc.identifier.citation	Ishola, D., Manno, D., Afolabi, M. O., Keshinro, B., Bockstal, V., Rogers, B., Owusu-Kyei, K., Serry-Bangura, A., Swaray, I. B., Lowe, B. S., Kowuor, D. O., Baiden, F., Mooney, T., Smout, E. M., Köhn, B., Otieno, G. T., Jusu, M., Foster, J., Samai, M. H., …, & Kowuor, D. O. (2021). Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial. The Lancet Infectious Diseases, 22(1), 97–109. https://doi.org/10.1016/s1473-3099(21)00125-0
dc.identifier.doi	10.1016/s1473-3099(21)00125-0
dc.identifier.uri	https://doi.org/10.1016/s1473-3099(21)00125-0
dc.identifier.uri	https://dspace.njala.edu.sl/handle/20.500.144402/1869
dc.language.iso	en
dc.publisher	Elsevier BV
dc.relation.ispartof	The Lancet Infectious Diseases
dc.subject	Ebola vaccine
dc.title	Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
dc.type	Article

Collections